Microbot (MBOT) signs a clinical trial agreement with the Baptist Hospital of Miami for its LIBERTY Endovascular Robotic Surgical System as a part of its Investigational Device Exemption.
As the third quarter of 2024 begins, U.S. stocks are showing signs of resilience with notable gains, despite underlying concerns about sector imbalances and interest rate uncertainties. In this context, growth companies with high insider ownership can be particularly compelling, as significant insider stakes often signal confidence in the company's future prospects from those who know it best.
Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.